Core Viewpoint - The Invesco S&P MidCap 400 Pure Value ETF (RFV) is a smart beta ETF that aims to provide broad exposure to the Mid Cap Value category, with a focus on stocks exhibiting strong value characteristics [1][5]. Fund Overview - RFV was launched on March 1, 2006, and has accumulated over $267.03 million in assets, categorizing it as an average-sized ETF in its segment [1][5]. - The fund is managed by Invesco and seeks to match the performance of the S&P MidCap 400 Pure Value Index, which measures securities with strong value characteristics within the S&P MidCap 400 Index [5]. Cost Structure - RFV has an annual operating expense ratio of 0.35%, which is competitive within its peer group [6]. - The fund's 12-month trailing dividend yield is 1.16% [6]. Sector Exposure and Holdings - The ETF's largest allocation is in the Consumer Discretionary sector, comprising approximately 26.3% of the portfolio, followed by Industrials and Financials [7]. - Concentrix Corp (CNXC) is the top holding at about 4.55% of total assets, with the top 10 holdings accounting for approximately 30.93% of RFV's total assets [8]. Performance Metrics - Year-to-date, RFV has increased by roughly 6.6%, and it has risen approximately 10.52% over the last 12 months as of July 29, 2025 [10]. - The fund has a beta of 1.17 and a standard deviation of 22.28% over the trailing three-year period, indicating a higher risk profile [10]. Alternatives - While RFV is a viable option for investors looking to outperform the Mid Cap Value segment, alternatives such as the iShares Russell Mid-Cap Value ETF (IWS) and the Vanguard Mid-Cap Value ETF (VOE) are also available [11][12]. - IWS has $13.61 billion in assets and an expense ratio of 0.23%, while VOE has $18.38 billion in assets with a lower expense ratio of 0.07% [12].

Core Insights - The FlexShares US Quality Large Cap ETF (QLC) debuted on September 23, 2015, and provides broad exposure to the Style Box - Large Cap Blend category of the market [1] Fund Overview - QLC is managed by Flexshares and has accumulated over $549.95 million in assets, positioning it as an average-sized ETF in its category [5] - The fund aims to match the performance of the Northern Trust Quality Large Cap Index, which focuses on large-cap securities with better quality, attractive valuation, and positive momentum [6] Cost Structure - The annual operating expense ratio for QLC is 0.25%, which is competitive with most peer products [7] - The ETF has a 12-month trailing dividend yield of 0.92% [7] Sector Exposure and Holdings - QLC has a significant allocation in the Information Technology sector, comprising approximately 33.7% of the portfolio [8] - The top three sectors also include Financials and Telecom [8] - Nvidia Corp (NVDA) is the largest holding at about 7.02% of total assets, followed by Apple Inc (AAPL) and Microsoft Corp (MSFT) [9] - The top 10 holdings represent around 36.23% of total assets under management [9] Performance Metrics - As of July 25, 2025, QLC has increased by approximately 10.27% year-to-date and 19.7% over the past year [10] - The ETF has traded between $56.84 and $72.92 in the last 52 weeks [10] - QLC has a beta of 0.99 and a standard deviation of 16.79% over the trailing three-year period, indicating medium risk [10] Alternatives - Other ETFs in the same space include SPDR S&P 500 ETF (SPY) and Vanguard S&P 500 ETF (VOO), with assets of $653.02 billion and $701.38 billion respectively [11] - SPY has an expense ratio of 0.09% while VOO charges 0.03% [11]

Core Viewpoint - The Invesco Biotechnology & Genome ETF (PBE) is designed to provide broad exposure to the Health Care ETFs category, focusing on biotechnology and genome sectors [1][5]. Fund Overview - PBE was launched on June 23, 2005, and is managed by Invesco, with assets totaling approximately $222.64 million, categorizing it as an average-sized ETF in the Health Care sector [1][5]. - The fund aims to match the performance of the Dynamic Biotechnology & Genome Intellidex Index, which evaluates companies based on various investment merit criteria [5][6]. Cost Structure - PBE has an annual operating expense ratio of 0.58%, which is competitive within its peer group, and a 12-month trailing dividend yield of 0.26% [7]. Sector Exposure and Holdings - The ETF has a significant allocation in the Healthcare sector, comprising about 99.8% of its portfolio [8]. - Illumina Inc (ILMN) represents approximately 5.81% of total assets, with the top 10 holdings accounting for about 47.68% of total assets under management [9]. Performance Metrics - As of July 22, 2025, PBE has experienced a year-to-date loss of approximately -3.56% and a one-year decline of about -6.19% [11]. - The fund has traded between $56.01 and $72.24 over the past 52 weeks, with a beta of 0.76 and a standard deviation of 21.29% over the trailing three-year period, indicating a higher risk profile [11]. Alternatives - Other ETFs in the biotechnology space include SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB), which have larger asset bases of $4.65 billion and $5.28 billion respectively, and lower expense ratios of 0.35% and 0.45% [12][13].

Core Viewpoint - The SPDR S&P Aerospace & Defense ETF (XAR) is a smart beta ETF designed to provide broad exposure to the aerospace and defense sector, with a focus on outperforming traditional market-cap weighted indices [1][5]. Fund Overview - XAR was launched on September 28, 2011, and is managed by State Street Global Advisors, amassing over $3.79 billion in assets, making it one of the larger ETFs in the Industrials category [1][5]. - The fund aims to match the performance of the S&P Aerospace & Defense Select Industry Index, which is a modified equal weight index representing the aerospace and defense sub-industry of the S&P Total Stock Market Index [6]. Cost and Expenses - The annual operating expenses for XAR are 0.35%, positioning it as one of the least expensive options in its category [7]. - The fund has a 12-month trailing dividend yield of 0.51% [7]. Sector Exposure and Holdings - XAR's portfolio is entirely allocated to the Industrials sector, with its top holdings including Archer Aviation Inc (5.15%), Aerovironment Inc, and Curtiss Wright Corp, which together account for approximately 45.28% of total assets [8][9]. Performance Metrics - As of July 17, 2025, XAR has gained about 31.34% year-to-date and approximately 46.4% over the past year, with a trading range between $140.71 and $217.46 during the last 52 weeks [11]. - The fund has a beta of 1.08 and a standard deviation of 21.19% over the trailing three-year period, indicating medium risk [11]. Alternatives - Other ETFs in the aerospace and defense space include Invesco Aerospace & Defense ETF (PPA) with $5.96 billion in assets and iShares U.S. Aerospace & Defense ETF (ITA) with $8.73 billion in assets, offering different expense ratios and strategies [12][13].

Core Insights - The Invesco S&P 100 Equal Weight ETF (EQWL) is designed to provide broad exposure to the Style Box - Large Cap Blend category and was launched on December 1, 2006 [1] - EQWL aims to match the performance of the Russell Top 200 Equal Weight Index, focusing on equal-weighted exposure to the largest 200 companies in the US equity market [5] Fund Overview - The fund is sponsored by Invesco and has accumulated over $1.52 billion in assets, making it one of the larger ETFs in its category [5] - EQWL has an annual operating expense of 0.25% and a 12-month trailing dividend yield of 1.74% [6] Sector Exposure and Holdings - The ETF has a significant allocation in the Financials sector, comprising approximately 19.2% of the portfolio, followed by Information Technology and Industrials [7] - Palantir Technologies Inc (PLTR) represents about 1.54% of total assets, with the top 10 holdings accounting for approximately 12.46% of total assets under management [8] Performance Metrics - Year-to-date, EQWL has increased by about 9.21% and is up roughly 17.25% over the last 12 months as of July 14, 2025 [10] - The fund has a beta of 0.94 and a standard deviation of 15.34% over the trailing three-year period, indicating a medium risk profile [10] Alternatives - Other ETFs in the same space include SPDR S&P 500 ETF (SPY) and Vanguard S&P 500 ETF (VOO), with SPY having $643.17 billion in assets and VOO at $689.4 billion [11] - SPY has an expense ratio of 0.09% while VOO charges 0.03% [11]